Skip to main content

Table 4 Overall drop-out rate and main reasons for treatment discontinuation in the NEONet database

From: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

Patient population (n = 221) Drop-out patients (70, 32 %) Patients under treatment (151, 38 %) p-value
Males, n (%) 25 (35.71) 68 (45.03) 0.0959
Females, n (%) 45 (64.29) 83 (54.97)
Age-years, mean (SD) 46.79 (14.82) 47.44 (13.11) 0.4904
Treatment duration-months, mean (SD) 27.69 (20.94) 27.54 (22.96) 0.4992
Reason for drop-out, n (%)
Lack of efficacy 18 (26)   
Patient’s decision discontinuation 34 (49)   
Efficacy 4 (6)   
Adverse events (local or systemic reactions) 5 (7)   
Onset of contraindications 6 (8)   
Patient moved to another referral center 3 (4)   
  1. NEONet North East Omalizumab Network, SD standard deviation